Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0006100,
umls-concept:C0022714,
umls-concept:C0030685,
umls-concept:C0086231,
umls-concept:C0243125,
umls-concept:C0391871,
umls-concept:C0680255,
umls-concept:C0699900,
umls-concept:C1283071,
umls-concept:C1511790,
umls-concept:C1514468,
umls-concept:C1515655,
umls-concept:C1963578,
umls-concept:C2745888
|
pubmed:issue |
3
|
pubmed:dateCreated |
1993-3-26
|
pubmed:abstractText |
We developed an enzyme immunoassay (EIA) specific for Arg1-Pro2-Pro3-Gly4-Phe5 ([1-5]-BK) for determination of the levels of this peptide in biological fluids. Previously developed EIAs for bradykinin (BK) and for des-Phe8-Arg9-BK ([1-7]BK) were also used. Incubation of rat plasma with glass powder resulted in the transient appearance of BK. A degradation product, [1-7]BK, could be detected in the incubation mixture for a longer period of time. When compared with BK and [1-7]BK, a larger amount of [1-5]BK was detectable even longer. In carrageenan-induced pleurisy in rats, which was associated with a peak rate of plasma exudation 5 hr after administration of carrageenan, BK was undetectable (< 160 pg/rat) in the pleural exudates. By contrast, [1-7]BK was detectable over the entire course of the inflammatory response. A larger amount of [1-5]BK was detectable. The peak level of [1-5]BK was 6050 +/- 1050 pg/rat, 5 hr after administration of carrageenan. Inhibition of the generation of BK by intrapleural administration of soy bean trypsin inhibitor (0.3 mg/rat) 30 min before collection of pleural fluid resulted in significant reductions in the levels of both [1-7]BK (by 51-65%) and [1-5]BK (by 63-79%) in the exudates 3, 7 and 19 hr after administration of carrageenan. Intraperitoneal administration of captopril (10 mg/kg) caused a marked reduction (by 98%) in levels of [1-5]BK in exudates 3 hr after administration of carrageenan. The reduction was accompanied by an increase in the level of BK up to 1250% of that in untreated rats. These results indicate that the newly developed EIA for [1-5]BK might be a useful tool for verifying the release of kinin in vivo.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Bradykinin,
http://linkedlifedata.com/resource/pubmed/chemical/Captopril,
http://linkedlifedata.com/resource/pubmed/chemical/Carrageenan,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Trypsin Inhibitor, Bowman-Birk...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0006-2952
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
9
|
pubmed:volume |
45
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
559-67
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8442755-Amino Acid Sequence,
pubmed-meshheading:8442755-Animals,
pubmed-meshheading:8442755-Biological Markers,
pubmed-meshheading:8442755-Bradykinin,
pubmed-meshheading:8442755-Captopril,
pubmed-meshheading:8442755-Carrageenan,
pubmed-meshheading:8442755-Immunoenzyme Techniques,
pubmed-meshheading:8442755-Male,
pubmed-meshheading:8442755-Molecular Sequence Data,
pubmed-meshheading:8442755-Peptide Fragments,
pubmed-meshheading:8442755-Pleural Effusion,
pubmed-meshheading:8442755-Pleurisy,
pubmed-meshheading:8442755-Rats,
pubmed-meshheading:8442755-Rats, Sprague-Dawley,
pubmed-meshheading:8442755-Sensitivity and Specificity,
pubmed-meshheading:8442755-Time Factors,
pubmed-meshheading:8442755-Trypsin Inhibitor, Bowman-Birk Soybean
|
pubmed:year |
1993
|
pubmed:articleTitle |
Detection of the degradation products of bradykinin by enzyme immunoassays as markers for the release of kinin in vivo.
|
pubmed:affiliation |
Department of Pharmacology, Kitasato University School of Medicine, Kanagawa, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|